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1975), the   evidence for the existence of specific mechanisms for 
vesicular storage is still controversial. Recently, both vesicular and 
non- vesicular release of TAs has been described (Kosa et al., 2000; 
Grandy, 2007). Due to their highly lipophilic nature (particularly 
of β-PEA) it is possible that TAs are mainly released from axon 
terminals by diffusion across the cell membrane, and that their 
levels reflect an equilibrium between synthesis and catabolism 
(Berry, 2004).
In invertebrates, TAs act as neurotransmitters to control a vari-
ety of physiological functions, including locomotion, feeding, and 
learning-associated behaviors (Roeder, 2005; Sotnikova et al., 2008). 
In contrast, in the mammalian brain the physiological role and 
the mechanisms of action of TAs remain poorly understood. They 
have been often regarded as by-products of amino acid metabolism 
with no clear functional relevance. TAs have also been considered 
to act as “false” neurotransmitters, due to their ability to release 
catecholamines in amphetamine-like manner, via their displace-
ment from synaptic vesicles and a reversal of plasma membrane 
transporters. It could be possible that by emptying synaptic vesicles 
(but with no affinity to monoaminergic receptors), TAs could pro-
duce, in the long run, a weakening of monoaminergic transmission. 
Trace amines (TAs) are a class of endogenous compounds strictly 
related to classic monoaminergic neurotransmitters, regarding 
the structure, metabolic pathways, cellular localization, and tis-
sue distribution (Berry, 2004; Grandy, 2007). The group includes 
β-phenylethylamine (β-PEA), tyramine (TYR), octopamine 
(OCT), synephrine (SYN), and tryptamine (TRP). TAs have been 
identified in several prokaryotic and eukaryotic organisms and in all 
investigated vertebrate and invertebrate species, including humans 
(Grandy, 2007). Their distribution in the mammalian brain strictly 
corresponds to the location of the main monoaminergic nuclei and 
their projecting areas.
Trace amines and biogenic amines share the same biosynthetic 
and metabolic pathways (Figure 1). They are produced in mono-
aminergic neurons from aromatic amino acids l-phenylalanine 
and tyrosine by amino acid decarboxylase (AADC), and are mainly 
catabolized by monoamine oxidase (MAO). Although the rates 
of synthesis are similar, TAs levels in the brain are two orders 
of magnitude lower than of classic monoaminergic neurotrans-
mitters, most likely due to a rapid turnover, with a half-life of 
approximately 30 s. Although synaptosomal localization of TAs has 
been reported (Baldessarini and Vogt, 1972; Boulton and Baker, 
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Trace amines (TAs) are a class of endogenous compounds strictly related to classic monoamine 
neurotransmitters with regard to their structure, metabolism, and tissue distribution. Although 
the presence of TAs in mammalian brain has been recognized for decades, until recently they 
were considered to be by-products of amino acid metabolism or as “false” neurotransmitters. 
The discovery in 2001 of a new family of G-protein-coupled receptors (GPCRs), namely trace 
amines receptors, has re-ignited interest in TAs. In particular, two members of the family, trace 
amine receptor 1 (TA1) and trace amine receptor 2 (TA2), were shown to be highly sensitive to 
these endogenous compounds. Experimental evidence suggests that TAs modulate the activity 
of catecholaminergic neurons and that TA dysregulation may contribute to neuropsychiatric 
disorders, including schizophrenia, attention deficit hyperactivity disorder, depression and 
Parkinson’s disease, all of which are characterized by altered monoaminergic networks. Here 
we review recent data concerning the electrophysiological effects of TAs on the activity of 
mesencephalic dopaminergic neurons. In the context of recent data obtained with TA1 receptor 
knockout mice, we also discuss the mechanisms by which the activation of these receptors 
modulates the activity of these neurons. Three important new aspects of TAs action have 
recently emerged: (a) inhibition of firing due to increased release of dopamine; (b) reduction of 
D2 and GABAB receptor-mediated inhibitory responses (excitatory effects due to disinhibition); 
and (c) a direct TA1 receptor-mediated activation of GIRK channels which produce cell membrane 
hyperpolarization. While the first two effects have been well documented in our laboratory, the 
direct activation of GIRK channels by TA1 receptors has been reported by others, but has not 
been seen in our laboratory (Geracitano et al., 2004). Further research is needed to address this 
point, and to further characterize the mechanism of action of TAs on dopaminergic neurons.
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doi: 10.3389/fnsys.2011.00056Recently, altered brain TAs levels have been reported in several 
 neuropsychiatric disorders, including schizophrenia, attention defi-
cit hyperactivity disorder (ADHD), depression, and Parkinson’s 
disease (PD), suggesting the involvement of these amines in patho-
physiology of monoaminergic systems (Branchek and Blackburn, 
2003; Burchett and Hicks, 2006).
Interest in TAs has been re-ignited following the discovery, in 
2001, of a novel class of G-protein-coupled receptors (GPCRs) that 
can be activated by these amines (Borowsky et al., 2001; Bunzow 
et al., 2001). The family of these “trace amine-associated receptors” 
(TAARs) consists of 15 members. However, only two, “trace amine 
receptor 1” (TA1) and “trace amine receptor 2” (TA2) (Maguire et al., 
2009) were shown to be sensitive to TAs. TA1, the best characterized 
receptor subtype, is coupled to Gs protein and exerts its intracellular 
effect by activation of the adenylyl cyclase (Borowsky et al., 2001; 
Bunzow et al., 2001).
Trace amine receptor 1 receptors are distributed in the CNS 
mainly in the monoaminergic systems, including mesencephalic 
dopaminergic (DAergic) neurons, where they are co-localized with 
dopamine (DA) transporter, DAT (Xie et al., 2007). However, the 
physiological role of TA1 receptors in the CNS in general, and in 
mesencephalic DAergic neurons in particular, is still not known. 
Recent studies suggest that these receptors modulate monoamin-
ergic transmission (Sotnikova et al., 2008; Xie and Miller, 2009) by 
acting on monoamine transporters (e.g., DAT) and/or by directly 
affecting neuronal firing (Lindemann et al., 2008; Bradaia et al., 
2009; Revel et al., 2011)
In addition to the TA1 receptor-mediated effects, other cellular 
mechanisms by which TAs affect the activity of monoaminergic 
neurons have been described. It has been reported that TAs can 
activate sigma (σ) receptors which inhibit K+ and Ca2+ ion chan-
nels (Nguyen et al., 1998; Zhang and Cuevas, 2002). In addition, 
in invertebrates TAs activate ligand-gated chloride channels (Pirri 
et al., 2009; Ringstad et al., 2009), suggesting that these endogenous 
compounds may modulate neuronal activity by triggering rapid 
ionic events also in vertebrates (Branicky and Schafer, 2009).
The first electrophysiological investigation of the effects of TAs 
on DAergic neuronal activity was an extracellular study conducted 
in midbrain slices by Pinnock (1983). He demonstrated an inhibi-
tory effect of TYR and OCT on firing of DAergic neurons in the 
Substantia nigra pars compacta (SNpc). A similar inhibitory effect 
was demonstrated for β-PEA in extracellular recordings conducted 
from the same group of neurons in vivo (Rodriguez and Barroso, 
1995). Intravenous applications of this amine (0.4–3.4 mg/kg) 
evoked a rapid but short-lasting (2–4 min) reduction in the firing 
frequency and in the occurrence of bursting.
Trace amines-induced inhibitory effect on firing of SNpc 
DAergic neurons has been further characterized in our labora-
tory (Geracitano et al., 2004). Using intracellular recordings with 
sharp microelectrodes in rat midbrain slices, we have demonstrated 
that TAs reduce the spontaneous firing rate of these neurons in a 
reversible and concentration-dependent manner (Figure 2A). The 
inhibitory effect was mediated by indirect activation of somatoden-
dritic D2 autoreceptors (D2 receptors located on DAergic neurons), 
consequent to increased DA release (Figure 2B). In particular, TAs-
induced efflux of newly synthesized DA from reserpine- insensitive 
pools, through a mechanism involving both the membrane 
 transporter-dependent and -independent mechanisms (Geracitano 
et al., 2004). More recent electrophysiological data demonstrated 
that TYR releases DA and indirectly activates D2 receptors also in 
subthalamic neurons (Zhu et al., 2007).
Trace amines can also modulate the activity of DAergic mesen-
cephalic neurons by a direct action on TA1 receptors. Patch-clamp 
recordings of ventral tegmental area (VTA) DAergic neurons in 
mice with a knockout of TA1 receptors (TA1 KO mice) have dem-
onstrated that these neurons have a higher spontaneous firing rate 
than in wild-type littermates (Lindemann et al., 2008; Bradaia 
et al., 2009). The increased firing rate of VTA neurons in TA1 KO 
mice supports the contention that, under normal conditions, 
there is a tonic inhibitory effect of TAs on DAergic neuron activ-
ity exerted through TA1 receptors. The inhibitory effect of TYR 
was not present in TA1 KO mice, further indicating that the slower 
firing in wild-type animals is mediated by constitutive activation 
of TA1 receptors by TAs (Lindemann et al., 2008). This was con-
firmed by using a selective TA1 receptor antagonist, N-(3-Ethoxy-
phenyl)-4-pyrrolidin-1-yl-3-trifluoromethyl-benzamide (EPPTB) 
that increased firing frequency of DAergic neurons in the VTA of 
wild-type mice, but not in TA1 KO mice (Bradaia et al., 2009). The 
latter study also demonstrated that TYR inhibits firing of these 
neurons by activation of TA1 receptors linked to G-protein-gated 
inwardly rectifying K+ channels (GIRK channels; also known as 
Kir3) and additional experiments performed with heterologously 
expressed receptor and channel proteins in Xenopus oocytes 
showed that the TA1-induced GIRK channel activation involves a 
PTX-insensitive, G-protein-dependent mechanism (most likely 
Gs; Bradaia et al., 2009).
Trace amines modify neuronal responses to classic neurotransmit-
ters, and thus exert neuromodulatory effects. Electrophysiological 
recordings conducted in our laboratory with sharp microelec-
trodes from SNpc DAergic neurons in midbrain slices revealed 
Figure 1 | Biosynthetic and catabolic enzymatic pathways of 
endogenous TAs (β-PeA and tyramine) and dopamine. The aromatic amino 
acids phenylalanine and tyrosine represent common precursors of TAs and 
dopamine. TAs are directly produced by decarboxylation by l-aromatic amino 
acid decarboxylase (AADC), while dopamine derives from l-DOPA, which is 
synthesized from tyrosine by tyrosine hydroxylase (TH). The catabolism is 
mainly via monoamine oxidase (MAO), with the production of phenyl acetic 
acid (PAA), hydroxyphenyl acetic acid (HPA), and dihydroxyphenyl acetic acid 
(DOPAC) from β-PEA, tyramine, and dopamine, respectively.
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presynaptic level. It is known that the inhibitory synaptic input to 
midbrain DAergic neurons mediated by GABA involves not only 
activation of postsynaptic GABAA receptors, but also presynaptic 
GABAB receptors which reduce GABA release (Giustizieri et al., 
2005). We have reported that both β-PEA and TYR antagonize the 
GABAB-dependent presynaptic inhibition of GABAergic inputs to 
SNpc DAergic neurons, by limiting the inhibitory effect of baclofen 
on the frequency of the spontaneous inhibitory postsynaptic cur-
rents (GABAA-induced sIPSCs; Berretta et al., 2005).
In addition, TAs have a neuromodulatory effect on the post-
synaptic responses mediated by D2 receptors in DAergic neurons. 
Using conventional intracellular and single-electrode voltage-clamp 
that TAs reduce GABAergic inhibitory  neurotransmission to these 
 neurons (Federici et al., 2005). In particular, both β-PEA and TYR, 
in micromolar concentrations, depressed the amplitude of electri-
cally evoked inhibitory postsynaptic potentials (IPSPs) mediated 
by GABAB receptors (Figure 2C), without modifying the GABAA-
evoked synaptic responses (Federici et al., 2005). Moreover, the cel-
lular responses (hyperpolarization/outward current) evoked by the 
stimulation of postsynaptic GABAB receptors with a GABAB ago-
nist baclofen were reduced by both β-PEA and TYR (Figure 2D). 
The TAs-induced depression of GABAB-mediated outward cur-
rents (involving GIRK channels) was neither dependent on pro-
tein kinases activity, nor on changes in the intracellular Ca2+ levels 
(Federici et al., 2005).
Figure 2 | electrophysiological effects of TAs on mesencephalic 
dopaminergic neurons. (A) β-PEA produces a reversible hyperpolarization 
and inhibition of spontaneous firing in mesencephalic dopaminergic neurons. 
(B) The TAs-induced inhibition of firing is mediated by indirect activation of D2 
autoreceptors, subsequent to the release of newly synthesized dopamine. 
The effect was absent in dopaminergic neurons treated with an inhibitor of 
DA synthesis (carbidopa, 300 μM for 30 min) and was blocked by a D2 
receptor antagonist, sulpiride (1 μM; data not shown). (C) The amplitude of 
electrically evoked inhibitory postsynaptic potentials (IPSPs) mediated by 
GABAB receptors is reduced by bath application of β-PEA (100 μM) and TYR 
(100 μM). (D) TAs reduce the outward currents produced by pressure 
application of the GABAB agonist, baclofen (arrows) in a reversible manner.  
(e) Negative modulatory effects of TAs on the D2-autoreceptors-mediated 
responses. The quinpirole-induced GIRK channel activation is reduced by  
both β-PEA and TYR in a reversible and concentration-dependent manner.  
(F) The D2/GIRK-mediated outward current evoked by TAs is not mediated  
by the activation of TA1 receptors, since it was present in TA1 receptor 
knockout mice.
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recordings from SNpc DAergic neurons, we have demonstrated 
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by quinpirole (a D2 receptor agonist) is reduced by concomitant 
application of β-PEA and TYR (Ledonne et al., 2010). The effect 
was reversible and concentration-dependent (Figure 2E). In an 
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of quinpirole-induced responses, we found that TAs effects were 
not mediated by TA1 (Figure 2F) and sigma (σ) receptors, nor 
were dependent on G-protein activation. Furthermore, inhibitory 
effects of TAs on D2 receptor-mediated responses could not be 
demonstrated in Xenopus oocytes expressing both D2 receptors 
and GIRK channel (Ledonne et al., 2010). The latter results suggest 
that the inhibitory effect of TAs on DAergic neurons depends on 
the activation of not yet identified neuron-specific sites.
All these results indicate that TAs control the activity of DAergic 
mesencephalic neurons through a complex mechanism that involves 
both indirect and direct inhibitory effects. Indirect effects are due 
to DA release through a reversal of DAT function, and possibly 
by a non-DAT-mediated mechanism. This causes an strengthening 
of DAergic inhibition mediated by somatodendritic D2 receptors 
(Geracitano et al., 2004). Direct inhibitory effects depend on activa-
tion of TA1 receptors. The results obtained by others in TA1 KO mice 
and using specific antagonists of these receptors indicated that TAs 
tonically inhibit the activity of DAergic VTA neurons (Bradaia et al., 
2009; Revel et al., 2011). However, we could not see a direct inhibi-
tory effect of TA in SNpc and VTA neurons in our experiments. A 
part the technical differences in recording the dopaminergic cells 
(intracellular versus patch-clamp) we do not have a suitable explana-
tion to account for the discrepancy between these and our results.
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